Adaptive Biotechnologies Corporation $ADPT Holdings Trimmed by Peregrine Capital Management LLC

Peregrine Capital Management LLC reduced its position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 25.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 522,802 shares of the company’s stock after selling 179,909 shares during the quarter. Peregrine Capital Management LLC owned 0.34% of Adaptive Biotechnologies worth $7,821,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. SG Americas Securities LLC grew its holdings in shares of Adaptive Biotechnologies by 82.5% during the third quarter. SG Americas Securities LLC now owns 68,113 shares of the company’s stock valued at $1,019,000 after buying an additional 30,785 shares in the last quarter. JTC Employer Solutions Trustee Ltd boosted its position in Adaptive Biotechnologies by 129.7% during the 3rd quarter. JTC Employer Solutions Trustee Ltd now owns 11,735 shares of the company’s stock worth $176,000 after acquiring an additional 6,626 shares during the period. Bouvel Investment Partners LLC grew its stake in Adaptive Biotechnologies by 2.2% during the 3rd quarter. Bouvel Investment Partners LLC now owns 42,878 shares of the company’s stock valued at $641,000 after acquiring an additional 904 shares in the last quarter. Yarbrough Capital LLC purchased a new position in Adaptive Biotechnologies during the 3rd quarter valued at about $427,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Adaptive Biotechnologies in the 3rd quarter valued at about $809,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Stock Down 1.3%

NASDAQ ADPT opened at $15.76 on Friday. The stock has a market capitalization of $2.41 billion, a PE ratio of -29.18 and a beta of 2.18. Adaptive Biotechnologies Corporation has a 12-month low of $5.97 and a 12-month high of $20.76. The company has a 50 day moving average price of $16.45 and a two-hundred day moving average price of $14.29.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. The business had revenue of $93.97 million for the quarter, compared to the consensus estimate of $58.76 million. During the same quarter last year, the firm earned ($0.22) EPS. Adaptive Biotechnologies’s revenue for the quarter was up 102.4% on a year-over-year basis. As a group, equities analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Insider Buying and Selling

In other news, insider Harlan S. Robins sold 10,000 shares of the company’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.44, for a total transaction of $164,400.00. Following the completion of the sale, the insider owned 1,222,312 shares in the company, valued at approximately $20,094,809.28. This represents a 0.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Francis Lo sold 3,125 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $16.08, for a total value of $50,250.00. Following the completion of the transaction, the insider directly owned 315,978 shares in the company, valued at $5,080,926.24. The trade was a 0.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 1,358,650 shares of company stock valued at $23,122,398. 6.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several analysts recently commented on ADPT shares. JPMorgan Chase & Co. raised their price target on shares of Adaptive Biotechnologies from $17.00 to $20.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. BTIG Research increased their target price on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Guggenheim assumed coverage on shares of Adaptive Biotechnologies in a research note on Tuesday, September 30th. They set a “buy” rating and a $20.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, October 8th. Finally, Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research note on Wednesday. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and a consensus price target of $17.11.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.